Carol Gallagher, Pharm.D.

Carol Gallagher Pharm.D.

Partner, New Enterprise Associates

Dr. Gallagher is currently the lead director of Atara Biotherapeutics and Chairman of Millendo Therapeutics. She also serves as a Director at PIONYR Immunotherapeutics, Annexon, XOC Pharmaceuticals, QPEX Biopharma, and Chromacode. She previously served as a Director at Aragon Pharmaceuticals, Seragon Pharmaceuticals, AnaptysBio and eFFECTOR Therapeutics.

Dr. Gallagher joined New Enterprise Associates as a Partner in 2014. From 2008-2011, Dr. Gallagher was the president and CEO of Calistoga Pharmaceuticals, which developed the first-in-class cancer therapeutic, CAL-101, and was acquired by Gilead Sciences in 2011. CAL-101 was approved as ZYDELIG in the US and Europe in 2014. Earlier in her career, she held commercial and drug development roles within Eli Lilly, Amgen, Agouron, Pfizer and Biogen Idec. She studied chemistry at Vanderbilt University and then attained her Bachelor of Science and Doctor of Pharmacy degrees from the College of Pharmacy at the University of Kentucky.

Turning Point Therapeutics is now a
Bristol Myers Squibb company

Select OK for information about Turning Point Therapeutics.

Select BMS to learn more about Bristol Myers Squibb